Role of farnesoid X receptor and bile acids in alcoholic liver disease

Acta Pharmaceutica Sinica B

Volumn 5, Issue 2, 2015, Pages 158-167

  Manley, Sharon ^a   Ding, Wenxing ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Alcoholic liver disease; Autophagy; Bile acids; Farnesoid X receptor; FoxO3

Indexed keywords

BILE ACID; CHOLESTEROL 7ALPHA MONOOXYGENASE; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GAMMA GLUTAMYLTRANSFERASE; LIVER RECEPTOR HOMOLOG 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TAUROCHOLIC ACID; TRANSCRIPTION FACTOR FKHRL1; URSODEOXYCHOLIC ACID;

ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; AUTOPHAGY; BILE ACID SYNTHESIS; GENETIC TRANSCRIPTION; HEPATITIS; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; MACROAUTOPHAGY; MICROBIOME; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PATHOGENESIS; REVIEW; STEATOSIS;

EID: 84947202485     PISSN: 22113835     EISSN: 22113843     Source Type: Journal    
DOI: 10.1016/j.apsb.2014.12.011     Document Type: Review

References (145)

1. Ding WX, Manley S, Ni HM The emerging role of autophagy in alcoholic liver disease. Exp Biol Med 2011, 236:546-556.
2. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011, 141:1572-1585.
3. Williams JA, Manley S, Ding WX. New advances in molecular mechanisms and emerging therapeutic targets in alcoholic liver diseases. World J Gastroenterol 2014, 20:12908-12933.
4. Li Y, Wang S, Ni HM, Huang HQ, Ding WX. Autophagy in alcohol-induced multiorgan injury: mechanisms and potential therapeutic targets. BioMed Res Int 2014, 2014:498491.
5. Wilfred de Alwis NM, Day CP. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis 2007, 27:44-54.
6. Tsukamoto H, Machida K, Dynnyk A, Mkrtchyan H. "Second hit" models of alcoholic liver disease. Semin Liver Dis 2009, 29:178-187.
7. O'Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Hepatology 2010, 51:307-328.
8. Tung BY, Carithers R.L.Jr Cholestasis and alcoholic liver disease. Clin Liver Dis 1999, 3:585-601.
9. Modica S, Gadaleta RM, Moschetta A. Deciphering the nuclear bile acid receptor FXR paradigm. Nucl Recept Signal 2010, 8:e005.
10. Zhou H, Hylemon PB. Bile acids are nutrient signaling hormones. Steroids 2014, 86:62-68.
11. Li TG, Chiang JYL. Bile acid signaling in liver metabolism and diseases. J Lipids 2012, 2012:754067.
12. Li TG, Chiang JYL Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev 2014, 66:948-983.
13. Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995, 81:687-693.
14. Seol W, Choi HS, Moore DD. Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors. Mol Endocrinol 1995, 9:72-85.
15. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, et al. Identification of a nuclear receptor for bile acids. Science 1999, 284:1362-1365.
16. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999, 284:1365-1368.
17. Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999, 3:543-553.
18. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science 2001, 294:1866-1870.
19. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009, 89:147-191.
20. Laffitte BA, Kast HR, Nguyen CM, Zavacki AM, Moore DD, Edwards PA. Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J Biol Chem 2000, 275:10638-10647.
21. Kim I, Ahn SH, Inagaki T, Choi M, Ito S, Guo GL, et al. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res 2007, 48:2664-2672.
22. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005, 2:217-225.
23. Song KH, Li T, Owsley E, Strom S, Chiang JY. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7α-hydroxylase gene expression. Hepatology 2009, 49:297-305.
24. Maloney PR, Parks DJ, Haffner CD, Fivush AM, Chandra G, Plunket KD, et al. Identification of a chemical tool for the orphan nuclear receptor FXR. J Med Chem 2000, 43:2971-2974.
25. Flatt B, Martin R, Wang TL, Mahaney P, Murphy B, Gu XH, et al. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J Med Chem 2009, 52:904-907.
26. Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 2000, 6:517-526.
27. Lee FY, Lee H, Hubbert ML, Edwards PA, Zhang Y. FXR, a multipurpose nuclear receptor. Trends Biochem Sci 2006, 31:572-580.
28. Sanyal S, Båvner A, Haroniti A, Nilsson LM, Lundåsen T, Rehnmark S, et al. Involvement of corepressor complex subunit GPS2 in transcriptional pathways governing human bile acid biosynthesis. Proc Natl Acad Sci USA 2007, 104:15665-15670.
29. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000, 102:731-744.
30. Glover SC, McPhie JL, Brunt PW. Cholestasis in acute alcoholic liver disease. Lancet 1977, 2:1305-1307.
31. Lefevre AF, DeCarli LM, Lieber CS. Effect of ethanol on cholesterol and bile acid metabolism. J Lipid Res 1972, 13:48-55.
32. Vendemiale G, Jayatilleke E, Shaw S, Lieber CS. Depression of biliary glutathione excretion by chronic ethanol feeding in the rat. Life Sci 1984, 34:1065-1073.
33. Wu W, Zhu B, Peng X, Zhou M, Jia D, Gu J. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease. Biochem Biophys Res Commun 2014, 443:68-73.
34. Xie G, Zhong W, Li H, Li Q, Qiu Y, Zheng X, et al. Alteration of bile acid metabolism in the rat induced by chronic ethanol consumption. FASEB J 2013, 27:3583-3593.
35. Hofmann AF, Roda A. Physicochemical properties of bile acids and their relationship to biological properties: an overview of the problem. J Lipid Res 1984, 25:1477-1489.
36. Dawson PA, Lan T, Rao A. Bile acid transporters. J Lipid Res 2009, 50:2340-2357.
37. Kerai MD, Waterfield CJ, Kenyon SH, Asker DS, Timbrell JA. Taurine: protective properties against ethanol-induced hepatic steatosis and lipid peroxidation during chronic ethanol consumption in rats. Amino Acids 1998, 15:53-76.
38. Axelson M, Mörk B, Sjövall J. Ethanol has an acute effect on bile acid biosynthesis in man. FEBS Lett 1991, 281:155-159.
39. Nilsson LM, Sjövall J, Strom S, Bodin K, Nowak G, Einarsson C, et al. Ethanol stimulates bile acid formation in primary human hepatocytes. Biochem Biophys Res Commun 2007, 364:743-747.
40. Chanda D, Kim YH, Li T, Misra J, Kim DK, Kim JR, et al. Hepatic cannabinoid receptor type 1 mediates alcohol-induced regulation of bile acid enzyme genes expression via CREBH. PLoS One 2013, 8:e68845.
41. Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 2000, 6:507-515.
42. Ni HM, Du K, You M, Ding WX. Critical role of FoxO3a in alcohol-induced autophagy and hepatotoxicity. Am J Pathol 2013, 183:1815-1825.
43. You M, Liang X, Ajmo JM, Ness GC. Involvement of mammalian sirtuin 1 in the action of ethanol in the liver. Am J Physiol Gastrointest Liver Physiol 2008, 294:G892-G898.
44. Mezey E. Dietary fat and alcoholic liver disease. Hepatology 1998, 28:901-905.
45. Haigis MC, Guarente LP. Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Genes Dev 2006, 20:2913-2921.
46. Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR, et al. 6α-Ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002, 45:3569-3572.
47. Lívero FA, Stolf AM, Dreifuss AA, Bastos-Pereira AL, Chicorski R, de Oliveira LG, et al. The FXR agonist 6ECDCA reduces hepatic steatosis and oxidative stress induced by ethanol and low-protein diet in mice. Chem Biol Interact 2014, 217:19-27.
48. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004, 113:1408-1418.
49. Langhi C, Pedraz-Cuesta E, Haro D, Marrero PF, Rodríguez JC. Regulation of human class I alcohol dehydrogenases by bile acids. J Lipid Res 2013, 54:2475-2484.
50. Manley S, Ni HM, Williams JA, Kong B, DiTacchio L, Guo G, et al. Farnesoid X receptor regulates forkhead Box O3a activation in ethanol-induced autophagy and hepatotoxicity. Redox Biol 2014, 2:991-1002.
51. Kong B., Zhan L., Shen J., Forostyan T., Wang L., Ding W.X., et al. Hepatoprotective effects of farnesoid X receptor in a mouse chronic alcohol feeding model. Hepatology 2014, 60:766A-771A.
52. Montet AM, Oliva L, Beaugé F, Montet JC. Bile salts modulate chronic ethanol-induced hepatotoxicity. Alcohol Alcohol 2002, 37:25-29.
53. Kim YH, Shin MJ. Effects of high taurocholate load on activities of hepatic alcohol metabolizing enzymes. Exp Mol Med 2002, 34:123-130.
54. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002, 36:525-531.
55. Neuman MG, Cameron RG, Shear NH, Bellentani S, Tiribelli C. Effect of tauroursodeoxycholic and ursodeoxycholic acid on ethanol-induced cell injuries in the human Hep G2 cell line. Gastroenterology 1995, 109:555-563.
56. Clemens DL, Halgard CM, Miles RR, Sorrell MF, Tuma DJ. Establishment of a recombinant hepatic cell line stably expressing alcohol dehydrogenase. Arch Biochem Biophys 1995, 321:311-318.
57. Dai Y, Rashba-Step J, Cederbaum AI. Stable expression of human cytochrome P4502E1 in HepG2 cells: characterization of catalytic activities and production of reactive oxygen intermediates. Biochemistry 1993, 32:6928-6937.
58. Henzel K, Thorborg C, Hofmann M, Zimmer G, Leuschner U. Toxicity of ethanol and acetaldehyde in hepatocytes treated with ursodeoxycholic or tauroursodeoxycholic acid. Biochim Biophys Acta 2004, 1644:37-45.
59. Oliva L, Beaugé F, Choquart D, Montet AM, Guitaoui M, Montet JC. Ursodeoxycholate alleviates alcoholic fatty liver damage in rats. Alcohol Clin Exp Res 1998, 22:1538-1543.
60. Tabouy L, Zamora AJ, Oliva L, Montet AM, Beaugé F, Montet JC. Ursodeoxycholate protects against ethanol-induced liver mitochondrial injury. Life Sci 1998, 63:2259-2270.
61. Nguyen TD, Oliva L, Villard PH, Puyoou F, Sauze C, Montet AM, et al. Cyp2e1 and Cyp3a1/2 gene expression is not associated with the ursodeoxycholate effect on ethanol-induced lipoperoxidation. Life Sci 1999, 65:1103-1113.
62. Vendemiale G, Grattagliano I, Signorile A, Altomare E. Ethanol-induced changes of intracellular thiol compartmentation and protein redox status in the rat liver: effect of tauroursodeoxycholate. J Hepatol 1998, 28:46-53.
63. Lukivskaya OY, Maskevich AA, Buko VU. Effect of ursodeoxycholic acid on prostaglandin metabolism and microsomal membranes in alcoholic fatty liver. Alcohol 2001, 25:99-105.
64. Plevris JN, Hayes PC, Bouchier IAD. Ursodeoxycholic acid in the treatment of alcoholic liver disease. Eur J Gastroenterol Hepatol 1991, 3:653-656.
65. Pelletier G, Roulot D, Davion T, Masliah C, Causse X, Oberti F, et al. A randomized controlled trial of ursodeoxycholic acid in patients with alcohol-induced cirrhosis and jaundice. Hepatology 2003, 37:887-892.
66. Zhong W, Zhou ZX. Alterations of the gut microbiome and metabolome in alcoholic liver disease. World J Gastrointest Pathophysiol 2014, 5:514-522.
67. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 2014, 146:1513-1524.
68. Chen P, Schnabl B. Host-microbiome interactions in alcoholic liver disease. Gut Liver 2014, 8:237-241.
69. Gabbard SL, Lacy BE, Levine GM, Crowell MD. The impact of alcohol consumption and cholecystectomy on small intestinal bacterial overgrowth. Dig Dis Sci 2014, 59:638-644.
70. Bode JC, Bode C, Heidelbach R, Dürr HK, Martíni GA. Jejunal microflora in patients with chronic alcohol abuse. Hepatogastroenterology 1984, 31:30-34.
71. Casafont Morencos F, de las Heras Castaño G, Martín Ramos L, López Arias MJ, Ledesma F, Pons Romero F. Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci 1996, 41:552-556.
72. Yan AW, Fouts DE, Brandl J, Stärkel P, Torralba M, Schott E, et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology 2011, 53:96-105.
73. Bull-Otterson L, Feng W, Kirpich I, Wang Y, Qin X, Liu Y, et al. Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment. PloS One 2013, 8:e53028.
74. Väkeväinen S, Tillonen J, Salaspuro M, Jousimies-Somer H, Nuutinen H, Färkkilä M. Hypochlorhydria induced by a proton pump inhibitor leads to intragastric microbial production of acetaldehyde from ethanol. Aliment Pharmacol Ther 2000, 14:1511-1518.
75. Visapää JP, Tillonen J, Salaspuro M. Microbes and mucosa in the regulation of intracolonic acetaldehyde concentration during ethanol challenge. Alcohol Alcohol 2002, 37:322-326.
76. Baraona E, Julkunen R, Tannenbaum L, Lieber CS. Role of intestinal bacterial overgrowth in ethanol production and metabolism in rats. Gastroenterology 1986, 90:103-110.
77. Rao R. Endotoxemia and gut barrier dysfunction in alcoholic liver disease. Hepatology 2009, 50:638-644.
78. Mutlu EA, Gillevet PM, Rangwala H, Sikaroodi M, Naqvi A, Engen P.A., et al. Colonic microbiome is altered in alcoholism. Am J Physiol Gastrointest Liver Physiol 2012, 302:G966-G978.
79. Chen Y, Yang F, Lu H, Wang B, Chen Y, Lei D, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 2011, 54:562-572.
80. Kakiyama G, Hylemon PB, Zhou H, Pandak WM, Heuman DM, Kang DJ, et al. Colonic inflammation and secondary bile acids in alcoholic cirrhosis. Am J Physiol Gastrointest Liver Physiol 2014, 306:G929-G937.
81. Mutlu E, Keshavarzian A, Engen P, Forsyth CB, Sikaroodi M, Gillevet P. Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. Alcohol Clin Exp Res 2009, 33:1836-1846.
82. Forsyth CB, Farhadi A, Jakate SM, Tang Y, Shaikh M, Keshavarzian A. Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis. Alcohol 2009, 43:163-172.
83. Nanji AA, Khettry U, Sadrzadeh SM. Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver (disease). Proc Soc Exp Biol Med 1994, 205:243-247.
84. Komatsuzaki N, Shima J. Effects of live Lactobacillus paracasei on plasma lipid concentration in rats fed an ethanol-containing diet. Biosci Biotechnol Biochem 2012, 76:232-237.
85. Chang B, Sang LX, Wang Y, Tong J, Zhang D, Wang BY. The protective effect of VSL#3 on intestinal permeability in a rat model of alcoholic intestinal injury. BMC Gastroenterol 2013, 13:151.
86. Singh AK, Pandey SK, Naresh Kumar G. Pyrroloquinoline quinone-secreting probiotic Escherichia coli Nissle 1917 ameliorates ethanol-induced oxidative damage and hyperlipidemia in rats. Alcohol Clin Exp Res 2014, 38:2127-2137.
87. Kirpich IA, Solovieva NV, Leikhter SN, Shidakova NA, Lebedeva OV, Sidorov PI, et al. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol 2008, 42:675-682.
88. Stadlbauer V, Mookerjee RP, Hodges S, Wright GA, Davies NA, Jalan R. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol 2008, 48:945-951.
89. Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006, 47:241-259.
90. Hepner GW, Sturman JA, Hofmann AF, Thomas PJ. Metabolism of steroid and amino acid moieties of conjugated bile acids in man. 3. Cholyltaurine (taurocholic acid). J Clin Invest 1973, 52:433-440.
91. Shi X, Yao D, Chen C. Identification of N-acetyltaurine as a novel metabolite of ethanol through metabolomics-guided biochemical analysis. J Biol Chem 2012, 287:6336-6349.
92. Kurdi P, Kawanishi K, Mizutani K, Yokota A. Mechanism of growth inhibition by free bile acids in lactobacilli and bifidobacteria. J Bacteriol 2006, 188:1979-1986.
93. Islam KB, Fukiya S, Hagio M, Fujii N, Ishizuka S, Ooka T, et al. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology 2011, 141:1773-1781.
94. Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. Bile acids and the gut microbiome. Curr Opin Gastroenterol 2014, 30:332-338.
95. Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, Downes M, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A 2006, 103:3920-3925.
96. Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell 2010, 140:313-326.
97. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science 2000, 290:1717-1721.
98. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000, 19:5720-5728.
99. Ohsumi Y. Molecular dissection of autophagy: two ubiquitin-like systems. Nat Rev Mol Cell Biol 2001, 2:211-216.
100. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012, 8:445-544.
101. Yang Z, Klionsky DJ. Mammalian autophagy: core molecular machinery and signaling regulation. Curr Opin Cell Biol 2010, 22:124-131.
102. Manley S, Williams JA, Ding WX. Role of p62/SQSTM1 in liver physiology and pathogenesis. Exp Biol Med 2013, 238:525-538.
103. Komatsu M, Waguri S, Koike M, Sou YS, Ueno T, Hara T, et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 2007, 131:1149-1163.
104. Ni HM, Boggess N, McGill MR, Lebofsky M, Borude P, Apte U, et al. Liver-specific loss of Atg5 causes persistent activation of NRF2 and protects against acetaminophen-induced liver injury. Toxicol Sci 2012, 127:438-450.
105. Kirkin V, Lamark T, Sou YS, Bjørkøy G, Nunn JL, Bruun JA, et al. A role for NBR1 in autophagosomal degradation of ubiquitinated substrates. Mol Cell 2009, 33:505-516.
106. Reggiori F, Komatsu M, Finley K, Simonsen A. Selective types of autophagy. Int J Cell Biol 2012, 2012:156272.
107. Ding WX, Yin XM. Mitophagy: mechanisms, pathophysiological roles, and analysis. Biol Chem 2012, 393:547-564.
108. Czaja MJ, Ding WX, Donohue T.M.Jr., Friedman SL, Kim JS, Komatsu M, et al. Functions of autophagy in normal and diseased liver. Autophagy 2013, 9:1131-1158.
109. Yin XM, Ding WX, Gao W. Autophagy in the liver. Hepatology 2008, 47:1773-1785.
110. Ding WX. Role of autophagy in liver physiology and pathophysiology. World J Biol Chem 2010, 1:3-12.
111. Ding WX, Li M, Yin XM. Selective taste of ethanol-induced autophagy for mitochondria and lipid droplets. Autophagy 2011, 7:248-249.
112. Ding WX, Li M, Chen X, Ni HM, Lin CW, Gao W, et al. Autophagy reduces acute ethanol-induced hepatotoxicity and steatosis in mice. Gastroenterology 2010, 139:1740-1752.
113. Lin CW, Zhang H, Li M, Xiong X, Chen X, Chen X, et al. Pharmacological promotion of autophagy alleviates steatosis and injury in alcoholic and non-alcoholic fatty liver conditions in mice. J Hepatol 2013, 58:993-999.
114. Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci 2007, 120:2479-2487.
115. Arden KC. FOXO animal models reveal a variety of diverse roles for FOXO transcription factors. Oncogene 2008, 27:2345-2350.
116. Tikhanovich I, Cox J, Weinman SA. Forkhead box class O transcription factors in liver function and disease. J Gastroenterol Hepatol 2013, 28 Suppl 1:S125-S131.
117. Tzivion G, Dobson M, Ramakrishnan G. FoxO transcription factors; regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta 2011, 1813:1938-1945.
118. Sengupta A, Molkentin JD, Paik JH, DePinho RA, Yutzey KE. FoxO transcription factors promote cardiomyocyte survival upon induction of oxidative stress. J Biol Chem 2011, 286:7468-7478.
119. Sengupta A, Molkentin JD, Yutzey KE. FoxO transcription factors promote autophagy in cardiomyocytes. J Biol Chem 2009, 284:28319-28331.
120. Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, Del Piccolo P, et al. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab 2007, 6:458-471.
121. Zhao J, Brault JJ, Schild A, Cao P, Sandri M, Schiaffino S, et al. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab 2007, 6:472-483.
122. Tumurbaatar B, Tikhanovich I, Li Z, Ren J, Ralston R, Kuravi S, et al. Hepatitis C and alcohol exacerbate liver injury by suppression of FOXO3. Am J Pathol 2013, 183:1803-1814.
123. Tikhanovich I, Kuravi S, Campbell RV, Kharbanda KK, Artigues A, Villar MT, et al. Regulation of FOXO3 by phosphorylation and methylation in hepatitis C virus infection and alcohol exposure. Hepatology 2014, 59:58-70.
124. Zhang G, Park MA, Mitchell C, Walker T, Hamed H, Studer E, et al. Multiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signaling. J Biol Chem 2008, 283:24343-24358.
125. Roesly HB, Khan MR, Chen HDR, Hill KA, Narendran N, Watts GS, et al. The decreased expression of Beclin-1 correlates with progression to esophageal adenocarcinoma: the role of deoxycholic acid. Am J Physiol Gastrointest Liver Physiol 2012, 302:G864-G872.
126. Payne CM, Crowley-Skillicorn C, Holubec H, Dvorak K, Moyer MP, Garewal H, et al. Deoxycholate, an endogenous cytotoxin/genotoxin, induces the autophagic stress-survival pathway: implications for colon carcinogenesis. J Toxicol 2009, 2009:785907.
127. Manley S, Ni HM, Kong B, Apte U, Guo G, Ding WX. Suppression of autophagic flux by bile acids in hepatocytes. Toxicol Sci 2014, 137:478-490.
128. Ma K, Saha PK, Chan L, Moore DD. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006, 116:1102-1109.
129. Calkin AC, Tontonoz P. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat Rev Mol Cell Biol 2012, 13:213-224.
130. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008, 7:678-693.
131. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004, 10:355-361.
132. Göttlicher M, Widmark E, Li Q, Gustafsson JA. Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci U S A 1992, 89:4653-4657.
133. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci U S A 1993, 90:2160-2164.
134. Seok S, Fu T, Choi SE, Li Y, Zhu R, Kumar S, et al. Transcriptional regulation of autophagy by an FXR-CREB axis. Nature 2014, 516:108-111.
135. Lee JM, Wagner M, Xiao R, Kim KH, Feng D, Lazar MA, et al. Nutrient-sensing nuclear receptors coordinate autophagy. Nature 2014, 516:112-115.
136. Kim I, Morimura K, Shah Y, Yang Q, Ward JM, Gonzalez FJ. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 2007, 28:940-946.
137. Yang F, Huang X, Yi T, Yen Y, Moore DD, Huang W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res 2007, 67:863-867.
138. Inami Y, Waguri S, Sakamoto A, Kouno T, Nakada K, Hino O, et al. Persistent activation of NRF2 through p62 in hepatocellular carcinoma cells. J Cell Biol 2011, 193:275-284.
139. Takamura A, Komatsu M, Hara T, Sakamoto A, Kishi C, Waguri S, et al. Autophagy-deficient mice develop multiple liver tumors. Genes Dev 2011, 25:795-800.
140. Ni HM, Woolbright BL, Williams J, Copple B, Cui W, Luyendyk JP, et al. NRF2 promotes the development of fibrosis and tumorigenesis in mice with defective hepatic autophagy. J Hepatol 2014, 61:617-625.
141. Nakajima T, Kamijo Y, Tanaka N, Sugiyama E, Tanaka E, Kiyosawa K, et al. Peroxisome proliferator-activated receptor α protects against alcohol-induced liver damage. Hepatology 2004, 40:972-980.
142. Fischer M, You M, Matsumoto M, Crabb DW. Peroxisome proliferator-activated receptor alpha (PPARα) agonist treatment reverses PPARα dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice. J Biol Chem 2003, 278:27997-28004.
143. Kong L, Ren W, Li W, Zhao S, Mi H, Wang R, et al. Activation of peroxisome proliferator activated receptor alpha ameliorates ethanol induced steatohepatitis in mice. Lipids Health Dis 2011, 10:246.
144. Settembre C, De Cegli R, Mansueto G, Saha PK, Vetrini F, Visvikis O, et al. TFEB controls cellular lipid metabolism through a starvation-induced autoregulatory loop. Nat Cell Biol 2013, 15:647-658.
145. Aroor AR, Jackson DE, Shukla SD. Dysregulated phosphorylation and nuclear translocation of cyclic AMP response element binding protein (CREB) in rat liver after chronic ethanol binge. Eur J Pharmacol 2012, 679:101-108.